Home  /  Resource Library  /  Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma-Level Analysis of Multiple Randomized Trials (SEAL)

Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma-Level Analysis of Multiple Randomized Trials (SEAL)

Article discusses the use of progression free survival versus overall survival as surrogate endpoint for clinical trials involving first line treatment of DLBCL.